As Global Head of Research and Development and Chief Medical Officer, Bill Mezzanotte is responsible for developing and executing CSL Behring’s Research & Development strategy and portfolio, including the identification and development of all R&D platforms, skills and expertise necessary for success.
In April 2017, Bill joined CSL Behring as Head of Clinical Development, responsible for clinical science, statistics and clinical operations across the portfolio. Most recently he had served as Senior Vice President and Head of Development, where he oversaw regulatory, project management, clinical science & operations, plasma, recombinant protein and gene therapy pharmaceutical development activities worldwide.
Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas. Most recently at AstraZeneca he was Senior Vice President and Head of the Respiratory and Inflammation Therapeutic Area.
Bill’s career has been notable for his adaptability and success in different settings. He has been directly involved with 30 successful global approvals across 15 different products in 10 distinct therapeutic disease areas and representing 5 different platform approaches. Across a number of companies, he has established, grown and managed top performing, multinational teams and developed numerous senior leaders.
In 2020, Bill was named to the Board of Directors of the Philadelphia-based University City Science Center.
Bill holds an undergraduate degree from Villanova University, obtained his M.D. at the University of Pennsylvania and a Master of Public Health degree from Johns Hopkins University.
Bill is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine.